SPONSOR

Institute of Hematology & Blood Diseases Hospital, China

Total Trials

Recruiting

Phases

Phase 1, Phase 2, Phase 2, Phase 1, Phase 4, Phase 2, Phase 3

Conditions studied: Aplastic Anemia Myelodysplastic Syndromes Autoimmune Hemolytic Anemia Functional Near-Infrared Spectroscopy CML,Blast Phase Prolonged Cytopenia Following CAR-T Therapy Allergic Transfusion Reaction Acute Leukemia of Ambiguous Lineage Evan Syndrome Treatment

Institute of Hematology & Blood Diseases Hospital, China is a clinical research sponsor with 25 registered studies on ClinicalTrials.gov, of which 25 are actively recruiting participants. Research covers conditions including Aplastic Anemia, Myelodysplastic Syndromes, Autoimmune Hemolytic Anemia, Functional Near-Infrared Spectroscopy.

The trial portfolio spans Phase 1, Phase 2, Phase 2, Phase 1 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.

Frequently Asked Questions — Institute of Hematology & Blood Diseases Hospital, China

How many clinical trials has Institute of Hematology & Blood Diseases Hospital, China sponsored?

ClinicalMetric currently tracks 25 clinical trials sponsored by Institute of Hematology & Blood Diseases Hospital, China, of which 25 are actively recruiting participants. These trials cover conditions including Aplastic Anemia, Myelodysplastic Syndromes, Autoimmune Hemolytic Anemia. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.

What therapeutic areas does Institute of Hematology & Blood Diseases Hospital, China research focus on?

Institute of Hematology & Blood Diseases Hospital, China clinical trials span Aplastic Anemia, Myelodysplastic Syndromes, Autoimmune Hemolytic Anemia, Functional Near-Infrared Spectroscopy, CML,Blast Phase, and additional conditions. The research pipeline includes Phase 1, Phase 2, Phase 2, Phase 1 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.

How do I participate in a Institute of Hematology & Blood Diseases Hospital, China clinical trial?

To participate in a Institute of Hematology & Blood Diseases Hospital, China trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Institute of Hematology & Blood Diseases Hospital, China trials with current recruitment status updated daily.

Institute of Hematology & Blood Diseases Hospital, China

Frequently Asked Questions — Institute of Hematology & Blood Diseases Hospital, China

Clinical Trials by Institute of Hematology & Blood Diseases Hospital, China

Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS

Olverembatinib Combined With Venetoclax and Azacitidine in Blast Phase Ph Chromosome-positive CML

Autologous Hematopoietic Stem Cell Infusion for Prolonged Cytopenia After CAR-T Cell Therapy

Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions.

Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage

Anti-CD38 Antibody Treating Evans Syndrome

The Efficacy and Safety Study of CAR-T Cells for Functional Cure in HIV-1/AIDS Patients

SupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies

JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas

CM336 Plus Isatuximab for Newly Diagnosed Multiple Myeloma With Renal Impairment

GVM±R in Patients With Relapsed or Refractory Aggressive NHL.

A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia

Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease

Chidamide in Combination With Azacitidine, Liposomal Mitoxantrone, and Prednisone (CAMP Regimen) for the Treatment of Previously Untreated Nodal TFH Cell Lymphoma

A Clinical Study to Evaluate the Safety and Efficacy of CLL1 and CD38 Dual-Target CAR-T Cell Injection in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Multi-target Drugs Sequential Combination Therapy in Adults Patients With Newly Diagnosed Primary Immune Thrombocytopenia

YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma

Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALL

Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)

Longitudinal Cohort of Pediatric Primary Immune Thrombocytopenia (ITP)

An Open, Exploratory Clinical Study of CM336 in the Treatment of Immune Thrombocytopenia

Newly-diagnosed Low Risk Pediatric B-cell ALL Protocol

Gene Therapy for Chinese Hemophilia A

Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study

Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma